Latest filing published 17 Mar 2021 for Cue Biopharma, Inc., €54k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -37.1%Entry US$448.50 · Close at T+365 US$282.30
- -64.1%Entry US$464.40 · Close at T+365 US$166.50
- -53.3%Entry US$5,700.00 · Close at T+365 US$2,660.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Kenneth Pienta: trading record in brief
Kenneth Pienta is a declared insider at 2 companies; the most frequent names are Cue Biopharma, Inc. and Curis Inc. We count 15 filings; the first trade dates from 16 September 2013 and the latest from 16 March 2021.
In open-market terms, that means 4 purchases worth €123k on one side and 5 sales worth €457k on the other. The net balance comes to €333k on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 6 option exercises. 2021 to date brings 1 purchase and 5 sales.
Half of the purchases are above €33k and half below. Ninety days after publication, 4 purchases show a median change of -4.4%, with the price up in 50% of them. Past outcomes like these are no guarantee of what comes next.
The newest entry dates from 17 March 2021: an open-market sale of €5,555, in Cue Biopharma, Inc. The clock since the last published purchase (22 January 2021) now reads 2,117 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Kenneth Pienta
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 13,000 shares@ US$5.009.3% of flowCommon StockSEC:0001209191-21-021293:0
- 13,000 shares@ US$15.1028.1% of flowCommon StockSEC:0001209191-21-021293:1
- 439 shares@ US$5.000.3% of flowCommon StockSEC:0001209191-21-021293:2
- 439 shares@ US$15.090.9% of flowCommon StockSEC:0001209191-21-021293:3
- 16,000 shares@ US$2.866.4% of flowCommon StockSEC:0000899243-21-007232:0
- 16,000 shares@ US$15.1534.2% of flowCommon StockSEC:0000899243-21-007232:1
- 1,280 shares@ US$2.860.5% of flowCommon StockSEC:0000899243-21-007232:2
- 2,994 shares@ US$5.002.1% of flowCommon StockSEC:0000899243-21-007232:3
- 4,274 shares@ US$15.069.1% of flowCommon StockSEC:0000899243-21-007232:4
- 2,720 shares@ US$2.861.1% of flowCommon StockSEC:0000899243-21-007230:0
- 2,720 shares@ US$15.075.8% of flowCommon StockSEC:0000899243-21-002947:0Canonical exit: 20 Apr 2021 (T+90)
- 2,000 shares@ US$7.50100.0% of flowCommon StockSEC:0001209191-18-004591:0Canonical exit: 27 Mar 2018 (T+90)
- 10,000 shares@ US$4.37Common stockSEC:0001181431-13-057809:0Canonical exit: 15 Dec 2013 (T+90)
- 20,000 shares@ US$2.95Common stockSEC:0001181431-13-057810:0Canonical exit: 6 Feb 2014 (T+90)
14 of 14 declarations
